文献速递老年精神焦虑、强迫与应激相关障碍

老年人焦虑的药物治疗:系统综述与荟萃分析

Pharmacological treatment of anxiety in older adults: a systematic review and meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2025-01-01

该系统综述与荟萃分析纳入19项随机对照试验共2336名老年人,评估焦虑药物治疗效果。苯二氮䓬类证据非常不确定。

要点

  • 苯二氮䓬类可能减轻焦虑但证据非常不确定且偏倚风险高。

核心结论

  • 抗抑郁药在减轻老年人焦虑症状方面优于安慰剂或等待名单,证据支持其安全性和耐受性。
  • 苯二氮䓬类 efficacy 和安全性证据薄弱。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Cochrane Central、Embase、PsycINFO和CINAHL从建库至2024年4月23日。
  • 纳入19项随机对照试验,共2336名老年人(60岁及以上或平均年龄65岁及以上)。

主要发现

  • 苯二氮䓬类可能减轻焦虑症状对比安慰剂,但证据非常不确定且偏倚风险高。

临床怎么用

  • 临床决策可参考抗抑郁药作为老年人焦虑的有效治疗选择,需注意中等至低证据确定性。
  • 苯二氮䓬类使用应谨慎,因证据非常不确定且偏倚风险高。

局限性

  • 其他药物类别主要结局的荟萃分析无法进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anxiety and its disorders are common in later life. Given the known risks of psychopharmacological treatments in older adults, clinical decision making for anxiety management should be guided by the strongest available evidence. This study aimed to comprehensively synthesise evidence on the pharmacological treatment of anxiety in older adults. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Cochrane Central, Embase, PsycINFO, and CINAHL from database inception to April 23, 2024, for randomised controlled trials on pharmacological treatments for anxiety in older adults (aged 60 years or older, mean age 65 years or older, or subgroup analyses meeting these criteria). Primary outcomes included reduction in anxiety symptoms, or treatment response, or remission. Standardised mean differences (SMD) were calculated for continuous variables and absolute difference and risk ratio (RR) for dichotomous variables. The risk of bias was assessed using the Cochrane Risk of Bias tool, and the certainty of evidence rated using GRADE. People with lived experience were involved in conducting this research. This trial is registered with PROSPERO (CRD42023407837). FINDINGS: We identified 19 eligible studies, including 2336 participants, 1592 (68·15%) of whom were women and 722 (30·91%) men, and sex was not reported for the other 22 (0·94%) participants. Only eight of 19 studies reported on race or ethnicity, and study participants were predominantly White (1309 [91·6%] of 1428), and no studies reported outcomes related to gender. Antidepressants were more effective than placebo or waitlist control in reducing anxiety symptoms (SMD -1·19 [95% CI -1·80 to -0·58), with moderate certainty of evidence and substantial heterogeneity (I2 92·34%; p<0·0001). Antidepressants were also more effective than placebo or waitlist control in response or remission (RR 1·52 [95% CI 1·21 to 1·90]; absolute difference 146 per 1000 [95% CI 59 to 252]); with a low certainty of evidence and low heterogeneity (I2 8·09%; p=0·36). Planned subgroup analysis indicated selective serotonin reuptake inhibitors led to a greater reduction in anxiety symptoms (SMD -1·84 [95% CI -2·52 to -1·17]) compared with serotonin-norepinephrine reuptake inhibitors (SMD -0·46 [95% CI -0·65 to -0·27]), and there was no difference in response or remission. Benzodiazepines might reduce anxiety symptoms compared with placebo, but the evidence is very uncertain with high risk of bias. Meta-analyses for other drug classes for primary outcomes were not possible. INTERPRETATION: Antidepressants are more effective than placebo or waitlist for reducing anxiety symptoms, with evidence supporting their safety and tolerability in older adults. Evidence for the efficacy and safety of benzodiazepines is weak. These findings can guide evidence-based practice. FUNDING: Public Health Agency of Canada.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Neil-Sztramko SE, Levy A, Flint AJ, et al. Pharmacological treatment of anxiety in older adults: a systematic review and meta-analysis. Lancet Psychiatry. 2025. PMID: 40379362. doi:10.1016/S2215-0366(25)00100-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。